Genmab — Februar 2019
-
Om
-
Og så er der ofa, men det program har jeg helt opgivet at tænke på. Om ikke andet, så fordi royalty er nede på 10pct
-
Ok. Interessant. Det bliver spændende at følge.
-
Men axl og tf-adc er egentlig lidt odd-one-out programmer, da GEN ellers ikke gør sig i ADCer
-
Tak skal I have. De nævnte, RTOR og nogle resultater fra SC, så går vi da et år i møde med mange potentielle highlights.
-
Resten af pipelinen er bygget op om duo og hexa. Og måske senere hex-elect
-
-
EL this is also running but remember its a dead cat https://clinicaltrials.gov/ct2/show/NCT03098550?term=daratumumab&cond=solid&rank=1
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind